Nanomedicine Strategies for Remodeling the Solid Tumor Microenvironment: Stromal Targeting, Hypoxia Modulation, and Photodynamic Immunotherapy
核心洞察
A comprehensive review in Frontiers in Oncology (搜索) outlines how nanomedicine can remodel the solid tumor microenvironment through stromal targeting, hypoxia control, and photodynamic immune activation.
Cancer-associated fibroblasts (搜索), dense extracellular matrix, hypoxia, and immunosuppressive myeloid and lymphoid populations jointly limit drug delivery and treatment response in solid tumors.
The authors argue that biomarker-guided, mechanism-matched platforms with measurable microenvironmental endpoints—rather than ever-greater carrier complexity—offer the most realistic path to clinical translation.
The tumor microenvironment (TME) is more than a passive backdrop for malignant cells: stromal fibroblasts, extracellular matrix, abnormal vasculature, hypoxia, and immunosuppressive myeloid and lymphoid populations act together to limit both drug delivery and treatment response. In a review published in Frontiers in Oncology (搜索), Rauf and colleagues examine nanomedicine along three linked axes—stromal remodeling, hypoxia control, and photodynamic immune activation—and argue that the field must shift from a tumor-centric to a microenvironment-centric strategy to deliver durable clinical benefit in solid tumors.
Stromal Targeting: Reprogramming Rather Than Depleting
Cancer-associated fibroblasts (搜索) (CAFs) are the most prevalent stromal cell type in numerous solid tumors, and their heterogeneity poses a central design challenge. Transcriptional profiling has identified distinct CAF subsets, including myofibroblastic CAFs (myCAFs), characterized by high expression of alpha-smooth muscle actin (αSMA) and a contractile, ECM-depositing phenotype, and inflammatory CAFs (iCAFs), which secrete elevated levels of pro-inflammatory cytokines such as IL-6, IL-8, and CCL2. A third subset, antigen-presenting CAFs (apCAFs), expresses MHC class II and may perform immunomodulatory functions.
The authors caution that subtype-selective reprogramming is safer than wholesale depletion, which can worsen outcomes. "Because fibroblasts are heterogeneous, subtype-selective reprogramming is safer than wholesale depletion, which can worsen outcomes," they write. Fibroblast activation protein-alpha (搜索) (FAPα), a type II transmembrane serine protease highly expressed in CAFs but largely absent in normal adult tissues, represents an attractive target for therapeutic inhibition and targeted drug delivery. Preclinical studies using FAPα-targeted nanoparticles have demonstrated improved tumor penetration and superior therapeutic outcomes, particularly when combined with chemotherapy and immunotherapy.
Hypoxia Modulation: Addressing a Defining TME Feature
Hypoxia is a defining feature of the tumor microenvironment, with tissue oxygen tension typically under 5–10 mmHg in tumors versus 40–60 mmHg in healthy tissue. HIF signaling—chiefly HIF-1α (搜索) and HIF-2α (搜索)—sits at the core of the cellular response, driving more than 100 downstream effectors associated with angiogenesis (VEGF), metabolic reprogramming (GLUT1 and LDHA), invasion (MMPs), and treatment resistance.
Hypoxia is particularly detrimental to photodynamic therapy (PDT), which depends on molecular oxygen to produce cytotoxic reactive oxygen species. Conventional Type II PDT can burn through local oxygen faster than it is resupplied, deepening hypoxia in already compromised tissues. Nanomedicine offers complementary solutions: oxygen-generating carriers such as albumin-MnO2 nanoparticles that exploit acidic, H2O2-rich conditions to release oxygen; oxygen-delivering perfluorocarbon@porphyrin nanoparticles; hypoxia-triggered release systems; and oxygen-conserving Type I photochemical systems that produce radical species through electron- or hydrogen-transfer and remain active at lower oxygen tensions.
The authors emphasize that HIF-1α (搜索) and HIF-2α (搜索) have non-redundant, sometimes opposing transcriptional programs. The selective HIF-2α inhibitor belzutifan has shown that isoform-specific targeting works in susceptible diseases, but this does not mean HIF-2α blockade will help across all solid tumors.
Photodynamic Immunotherapy: Coupling Local Killing with Immune Activation
Nanoparticle-enabled PDT is distinguished by the combination of local tumor destruction and immunogenic cell death (ICD) with spatially controlled release of immunomodulators. Upon light activation, photosensitizers generate reactive oxygen species that induce ICD, releasing calreticulin, ATP, HMGB1, and tumor antigens that recruit and prime dendritic cells.
A consistent finding across preclinical studies is that the antigen generated by PDT must be accompanied by a secondary immune instruction. Representative platforms include core-shell nanoscale coordination polymers combining an oxaliplatin core with a pyrolipid shell and anti-PD-L1, which produced calreticulin exposure, tumor-specific IFN-γ T cells, increased CD8 infiltration, and abscopal regression in bilateral CT26/MC38 colorectal cancer models. A hypoxia-tolerant Type I polymeric photosensitizer combined with the STAT3 inhibitor niclosamide achieved higher dendritic cell maturation, higher CD8/Treg ratios, and improved survival in 4T1 breast cancer models.
The authors also situate this work within the broader immunotherapy landscape. In advanced melanoma (搜索), nivolumab plus ipilimumab achieved a 5-year overall survival of 52%, compared to 44% for nivolumab alone. In untreated melanoma, relatlimab plus nivolumab stretched median progression-free survival to 10.1 months from 4.6 months with nivolumab alone. In the randomized phase II PRINCE trial in metastatic pancreatic cancer, nivolumab plus chemotherapy met the primary 1-year overall survival endpoint at 57.7%, while sotigalimab plus chemotherapy reached 48.1% against a 35% historical benchmark.
Clinical Translation: Lessons from Failure
The translational record is instructive. A quantitative analysis of preclinical studies reported that median tumor delivery was approximately 0.7% of the injected nanoparticle dose, with wide variation across models and platforms. The enhanced permeability and retention (EPR) effect is not a uniform delivery mechanism, and protein-corona formation, off-target clearance, manufacturing complexity, and weak biomarker selection can each wipe out an apparent preclinical advantage.
Failed phase III trials set some of the most stringent design constraints. In hyaluronan-high metastatic pancreatic ductal adenocarcinoma (搜索) (PDAC), HALO-301 found that adding PEGPH20 to nab-paclitaxel/gemcitabine raised the response rate but did not improve overall survival (11.2 versus 11.5 months; HR 1.00) or progression-free survival (7.1 months in both arms). In MAESTRO, the hypoxia-activated prodrug evofosfamide with gemcitabine missed its primary overall survival endpoint (8.7 versus 7.6 months; HR 0.84; P = .059) despite encouraging phase II activity.
"Taken as a pair, they argue for validated spatial biomarkers, direct confirmation of target engagement or prodrug activation, respect for the context-dependent protective roles of stroma, and early testing of whether a mechanism actually improves delivery at metastatic and primary sites," the authors write.
The Path Forward
The authors conclude that the more realistic path forward is not ever-greater carrier complexity, but biomarker-guided, mechanism-matched platforms with measurable microenvironmental endpoints and a clear route to scalable production. Patient stratification is central: tumors with high FAP expression, collagen accumulation, abundant hyaluronan, or validated hypoxia signatures may be the best candidates for stromal or oxygen-responsive strategies.
Near-term progress will most likely come from focused platforms that solve a specific microenvironmental problem—such as stromal normalization or hypoxia relief—inside a well-defined patient group, rather than from elaborate systems that attempt to modulate every major component of the TME simultaneously. As the authors note, "The question is no longer whether nanomedicine can influence the tumor microenvironment; it is how swiftly we can translate these discoveries into meaningful clinical benefits for patients with solid tumors that remain untreatable."